{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062263","form_type":"8-K","ticker":"GRDX","cik":"0001604191","company_name":"GridAI Technologies Corp.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.184167+00:00","generated_at":"2026-06-01T21:07:41.483951+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"First Wave BioPharma changes name to Entero Therapeutics; ticker to ENTO effective May 17","bullets":["Name change from First Wave BioPharma to Entero Therapeutics effective May 17, 2024.","Nasdaq ticker symbol changes from FWBI to ENTO at market open on May 17.","Rebranding follows recent business combination with ImmunogenX, reflecting GI-focused pipeline.","Lead asset latiglutenase for celiac disease; Phase 3 trial expected to begin early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062263","json":"https://secwatch.observer/filing/0001104659-24-062263.json","markdown":"https://secwatch.observer/filing/0001104659-24-062263.md","text":"https://secwatch.observer/filing/0001104659-24-062263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/0001104659-24-062263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/tm2414628d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:07:41.483951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eba0aa87be84d2d4057ec2a383ca6027082dd055","claim":"GridAI Technologies Corp.: Company changed its corporate name from First Wave BioPharma, Inc. to Entero Therapeutics, Inc. via amendment to Amended and Restated Certificate of Incorporation (effective 2024-05-17).","evidence_excerpt":"On May 15, 2024, First Wave BioPharma, Inc. (the “Company”) filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from \"First Wave BioPharma, Inc.\" to \"Entero Therapeutics, Inc.\" (the \"Name Change Amendment\"). Pursuant ot the Name Change Amendment, this name change is effective as of May 17, 2024.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/0001104659-24-062263-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-05-17"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}